Overview

Ketamine and Neuropathic Pain

Status:
Unknown status
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
The primary outcome is to compare the analgesic efficacy of intravenous ketamine treatment to that of a placebo in patients with refractory neuropathic pain. The secondary outcomes are: 1. - To compare the additive analgesic efficacy of prior administration of magnesium sulfate to that of placebo and ketamine only, on the effectiveness of intravenous ketamine treatment, 2. - To study the evolution time of pain and analgesia after the intravenous administration of ketamine and placebo, 3. - To study the correlation of the analgesic response to administered products respectively ketamine, ketamine and magnesium sulfate, placebo.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Clermont-Ferrand
Treatments:
Ketamine
Magnesium Sulfate